The metabolism of MDA (3,4-methylenedioxyamphetamine), HMMA (3-hydroxy-4-methoxymethylamphetamine) and HME (3-hydroxy-4-methoxyethylamphetamin) of the popular designer drugs MDMA ('ecstasy', 3,4-methylenedioxymethamphetamine) and MDE ('eve', 3,4-methylenedioxyethylamphetamine) was determined in rat serum, whole blood and urine, as well as in whole brain structures (cortex and striatum) after subcutaneous administration of 20 mg/kg MDMA and MDE, respectively. MDMA and MDE were extracted from serum and homogenized brain structures using a solid-phase extraction procedure. The extracts were examined by a validated high-performance liquid chromatography procedure coupled with fluorimetric detection. Our results demonstrate that MDMA is metabolized to a higher degree than MDE, resulting in a higher concentration of neurotoxic dihydroxymetabolites and (S)-MDA. There was no difference between the metabolism of MDMA and MDE and its respective isomers. Different concentrations of the respective isomers of MDMA and MDE let us suggest an enantioselective metabolism for both MDMA and MDE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0304-3940(02)00776-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Determination of amphetamines in hair samples using microextraction by packed sorbent and gas chromatography-mass spectrometry.
Drug Test Anal
July 2024
Centro de Investigação em Ciências da Saúde, Faculdade de Ciências da Saúde da Universidade da Beira Interior (CICS-UBI), Covilhã, Portugal.
Several protocols for the analysis of amphetamine-type stimulants (ATS) in hair have been developed over the years, with microextraction by packed sorbent (MEPS) being used for drugs like opiates, cocaine and ketamine. However, concerning ATS determination in hair samples, this approach has only been applied so far to amphetamine (AMP) and methamphetamine (MAMP). This study aimed at developing and validating a MEPS-based procedure for the determination in hair of not only AMP and MAMP but also of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), 1-(1,3-benzodioxol-5-yl)propan-2-yl (ethyl)amine (MDE) and N-methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane (MBDB) as well.
View Article and Find Full Text PDFRace and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
J Psychopharmacol
January 2023
Department of Psychology, Harvard University, Cambridge, MA, USA.
Background: Psychedelics are receiving renewed attention within Western medicine as they represent potential treatments for many difficult-to-treat mental health disorders. However, psychedelic science is limited in its focus and inclusion of racial and ethnic minorities. Hence, this study examines whether race and ethnicity moderate the associations that naturalistic 3,4-methylenedioxymethamphetamine (MDMA)/ecstasy use and psilocybin use share with major depressive episodes (MDEs).
View Article and Find Full Text PDFLifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
J Psychopharmacol
January 2022
Department of Psychology, Harvard University, Cambridge, MA, USA.
Background: Depression is a major mental health issue worldwide, with high rates of chronicity and non-recovery associated with the condition. Existing treatments such as antidepressant medication and psychological treatments have modest effectiveness, suggesting the need for alternative interventions.
Aim: The aim of this study was to examine the relationships between MDMA (3,4-methylenedioxymethamphetamine)/ecstasy and psilocybin use and major depressive episodes (MDEs).
A new LC-MS/MS confirmation method for the determination of 17 drugs of abuse in oral fluid and its application to real samples.
Forensic Sci Int
July 2020
Fondazione IRCCS Istituto Neurologico Carlo Besta, Laboratory of Neurological Biochemistry and Neuropharmacology, Via Celoria 11, Milano 20133, Italy. Electronic address:
A new liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirmation method for the direct analysis of 17 drugs starting from 200μL of diluted oral fluid (OF), in a single chromatographic run, was developed and validated. Cocaine, benzoylecgonine (BEG), cocaethylene, Δ-9-tetrahydrocannabinol (Δ-9-THC), buprenorphine, 6-acetylmorphine (6AM), morphine, codeine, methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), methylenedioxyamphetamine (MDA), 3,4-Methylenedioxy-N-ethylamphetamine (MDE), ketamine, N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB) were determined in a chromatographic run of 12min only with no sample pre-treatment, after the addition of 15 different internal standards (ISs). The method met all requirements in terms of linearity, accuracy (precision and trueness), recovery, and stability requested by FDA guidelines.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!